Aldredge, Lakshi M.
Chamberlain, Winston D.
Shi, Vivian Y.
Funding for this research was provided by:
LEO Pharma Inc
Article History
Received: 6 July 2023
Accepted: 20 December 2023
First Online: 3 February 2024
Declarations
:
: Lakshi M. Aldredge is on the Board of Directors for the Society of Dermatology Nurse Practitioners and has served on Speakers’ Bureaus, Advisory Boards, or as a consultant for the following companies: AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, Inc., Eli Lilly and Company, Incyte Corporation, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, UCB. Winston D. Chamberlain is a medical advisor and/or investigator for Aslan Pharmaceuticals, Beyeonics, Cambium, Kowa, LEO Pharma, Noveome Biotherapeutics, BrightStar Therapeutics, Oyster Point, Regeneron, Neumora and Pfizer. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from AbbVie, Altus Lab/cQuell, Aristea Therapeutics, Boehringer Ingelheim, Burt’s Bees, Dermira, Ely Lilly, Galderma, GPSkin, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, MYOR, Novartis, Pfizer, Polyfins Techology, Regeneron, Sanofi Genzyme, Skin Actives Scientific, SUN Pharma, Target-PharmaSolutions, and UCB.
: This article does not contain any studies with human participants or animals performed by any of the authors.